Opmax announced that the company plans to issue shares and pay cash to purchase 100% of Pengli Biotech's shares and raise supporting capital. On December 8, 2025, the Shanghai Stock Exchange Reorganization Committee held a meeting to review the transaction application. The results were in line with the restructuring conditions and information disclosure requirements. The transaction still needs to be registered with the approval of the China Securities Regulatory Commission before it can be implemented. There is uncertainty about whether registration can be completed in the end and when.

Opmax announced that the company plans to issue shares and pay cash to purchase 100% of Pengli Biotech's shares and raise supporting capital. On December 8, 2025, the Shanghai Stock Exchange Reorganization Committee held a meeting to review the transaction application. The results were in line with the restructuring conditions and information disclosure requirements. The transaction still needs to be registered with the approval of the China Securities Regulatory Commission before it can be implemented. There is uncertainty about whether registration can be completed in the end and when.